iShares Biotechnology ETF

ProShare Advisors Increases Gilead Stake by 39.1% in Q4, Total Holdings Reach 2.2 Million Shares

Gilead Sciences Chief Communications Officer Johanna Mercier Sells Nearly 28k Shares for $3.55M

Truist Financial Cuts Regeneron Price Target, Sending Shares Gap Down

Regeneron's fianlimab combination fails Phase 3, shares plunge over 11%

Regeneron Partners with Parabilis for $125M Deal to Advance Antibody Conjugates

Insmed's New Drug BRINSUPRI Sales Surge 44%, CEO Lewis Reaffirms Growth Confidence

Revolution Medicines Pancreatic Cancer Drug Trial Shows Positive Results, US Cancer Center Launches Expanded Access Plan Amid Stock Fluctuation

Gilead Sciences Focuses on HIV Growth and Expands Oncology and Inflammation Pipeline via Acquisitions

Natera Co-founder Sheena Jonathan Sells Shares in Two Transactions in May

Regeneron Provides Update on Phase 3 Trial of Fianlimab Combination for Melanoma

Signatera™ CDx Receives FDA Approval as Companion Diagnostic for Muscle-Invasive Bladder Cancer

Oppenheimer Raises Biogen Price Target to $300, Maintains Outperform Rating

Gilead Sciences Prices $3 Billion Senior Unsecured Bond Offering

TD Cowen Reaffirms Buy Rating on Biogen with $215 Price Target

Biogen Finalizes Acquisition Agreements with Apellis: Establishes SYFOVRE Milestone CVR and Secures $2 Billion Loan

Biogen Advances Alzheimer's Drug to Late Trials Despite Mid-Stage Failure, Shares Jump 6%

Biogen Announces Positive Phase 2 Results for Ionis Partner Drug Diranersen in Alzheimer's Disease

Biogen announces Alzheimer's drug fails to meet primary endpoint in mid-stage trial

US Clinics Race to Enroll Patients in Revolution Medicines Pancreatic Cancer Drug Early Access Plan After FDA Approval

Gilead's Yeztugo Revenues Surged 73% QoQ, Exceeding Market Expectations

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

InMed Pharmaceuticals

Amesite

Meiwu Tech

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

CN Energy

NextNRG

MetaVia

Generation Income Properties

Co-Diagnostics

Pinned News

置顶新闻

EXCLUSIVE: Hoth Therapeutics To Rebrand To Pursue AI Chip Technologies

HOTH

LABU

Hoth Therapeutics Inc. plans to rebrand as Rocket One Inc. to focus on AI semiconductor technologies and ultra-low-power AI computing. The board unanimously approved this strategic shift, which includes securing exclusive rights to technologies from Virginia Commonwealth University. The company will maintain its biotechnology operations while addressing AI infrastructure challenges. Hoth's shares fell 9.69% to $0.55 in premarket trading, reflecting a 20.9% decline over the past month.

benzinga_article

Hoth Therapeutics

Direxion S&P Biotech Bull 3X

First Trust NYSE Arca Biotech Index Fd

SPDR S&P Biotech

Proshares Ultra Nasdaq Biotech

VanEck Biotech ETF

S&P 500

SBIO

ARKG

Saturn V Capital Management sold 822,007 shares of Dyne Therapeutics for approximately $14.17 million, reducing its stake to 966,609 shares valued at $17.52 million. Despite this sale, Dyne's stock has risen nearly 40% over the past year, outperforming the S&P 500. The company is focused on developing therapeutics for rare muscle diseases and has a strong cash position of $972.2 million, funding operations into 2028. Investors are advised to consider other stocks as Dyne was not included in a recent top 10 list by The Motley Fool.

nasdaq

Dyne Therapeutics

ALPS Medical Breakthrough

Ark Genomic Revolution ETF

Invesco Biotechnology & Genome ETF

Alumis

Amylyx Pharmaceuticals

Abivax SA

Vaxcyte

Pharvaris BV

Dyne Therapeutics Is Up 40%, but One Biotech Fund Just Disclosed Selling $14 Million Worth of Shares

OCUL

Saturn V Capital Management fully exited its position in Ocular Therapeutix, selling 1,504,880 shares for an estimated $14.34 million. The fund's reported assets fell by $18.27 million due to share sales and price changes. Ocular's recent performance has been mixed, with revenue growth lagging and net losses widening, despite positive clinical trial data. Investors are advised to consider other stocks, as Ocular was not included in a recent top investment list.

Ocular Therap

Netflix

NVIDIA

NVIDIA Corporation

What This Fund’s $14 Million Ocular Therapeutix Exit Could Signal for Investors

AMIX

MTVA

IBBQ

On Tuesday, Med Pharmaceuticals (NASDAQ:INM) saw a 127% increase to $1.54, while MetaVia (NASDAQ:MTVA) rose 58.54% to $1.76. Other gainers included Co-Diagnostics (NASDAQ:CODX) up 41.6% and Edesa Biotech (NASDAQ:EDSA) up 32.11%. Conversely, WORK Medical Tech Gr (NASDAQ:WOK) dropped 39% to $0.23, and Autonomix Medical (NASDAQ:AMIX) fell 25.43%. AIM ImmunoTech (AMEX:AIM) declined 18.02% to $0.33.

Autonomix Medical

WORK Medical Tech

Edesa Biotech

AIM ImmunoTech

iShares US Medical Devices

Health Care Select Sector SPDR

Invesco Nasdaq Biotechnology ETF

Adial Pharmaceuticals

Virax Biolabs

Akanda

Psyence Biomedical

Quantum Cyber NV

AIM IMMUNOTECH INC

AIM ImmunoTech Inc.

PSYENCE BIOMEDICAL LTD C/WTS 25/01/2029(TO PUR COM)

Mainz Biomed NV

12 Health Care Stocks Moving In Tuesday's Intraday Session

BeOne Medicines (NASDAQ:ONC) has achieved an annualized return of 26.69% over the past decade, outperforming the market by 13.23%. A $100 investment in ONC 10 years ago would now be worth $1,057.17, reflecting the significant impact of compounded returns. The company's current market capitalization stands at $29.88 billion.

Beigene

VG Health

iShares Global Healthcare

iShares US Pharma

Here's How Much $100 Invested In BeOne Medicines 10 Years Ago Would Be Worth Today

Sanofi reported 1.21 billion issued shares and 1.33 billion real voting rights as of April 30, 2026. Theoretical voting rights, including treasury shares, stood at 1.35 billion.

PUBT

Sanofi

Sanofi reports 1.21 billion issued shares, 1.33 billion real voting rights as of April 30

Sanofi has provided information regarding its total number of voting rights and shares as of April 30, 2026. The company has issued 1,212,212,936 shares, with 1,329,027,146 real voting rights (excluding treasury shares) and a theoretical total of 1,346,241,660 voting rights (including treasury shares). This information complies with French commercial regulations.

GlobeNewswire

Sanofi: Information concerning the total number of voting rights and shares - April 2026

Charles River Laboratories (CRL) shares have declined 18% in the past month, closing at $149.93, despite a 1-year total return of 6.05%. Analysts suggest the stock may be undervalued, with a fair value estimate of $313.61, while a DCF model indicates a lower value of $78.12. Investors are encouraged to weigh these differing perspectives and consider other investment opportunities in the healthcare sector.

Simplywall

Charles River Laboratorie

iShares US Healthcare Providers

Direxion S&P Biotech Bear 3X

iShares Genomics Immunology and Healthcare ETF

A Look At Charles River Laboratories (CRL) Valuation After Recent Share Price Weakness

SBFM

SBFMW

Sunshine Biopharma has successfully closed a public offering, raising approximately $6 million. The deal included 12 million common or pre-funded units priced at $0.5 each, bundled with two Series C warrants. These warrants are immediately exercisable at $0.5 for five years, potentially generating an additional $12 million. The net proceeds will be used for general corporate purposes and working capital.

Sunshine Biopharma

SUNSHINE BIOPHARMA INC C/WTS (TO PUR COM)

ACCESS Newswire

Sunshine Biopharma closes USD 6 million public offering with Series C warrants

CBUS

Cibus (CBUS) reported a Q1 2026 net loss of $21.2 million, significantly reduced from $49.4 million year-over-year. The company raised $37 million to support its commercial objectives, with a cash position of $30.3 million. Key developments include a planned 2027 Latin America rice launch and expanded partnerships in sustainable ingredients. Regulatory progress in Ecuador and Peru supports market access, while U.S. launch delays to 2029 are noted. Management emphasizes cost discipline and a financial runway extending into Q1 2027.

Motley Fool

Cibus

Cibus (CBUS) Q1 2026 Earnings Transcript

NBTX

Qube Research & Technologies has disclosed a 0.58% net short position in Nanobiotix shares, as per an AMF filing.

Nanobiotix SA

Qube Research & Technologies discloses net short position in Nanobiotix shares

iShares Biotechnology ETF(IBB.US)